IRWD News and Press, Ironwood Pharmaceuticals Inc. From 02/27/23

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences: Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET at the Boston Marriott Copley Place ...

Summary Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality. I look at iShares Genomics Immunology and Healthcare ETF, an ETF in genomics and immunology. 10 stocks cheaper than their peers in Nov...

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2022 Earnings Conference Call February 16, 2023, 08:30 ET Company Participants Matt Roache - Director, IR Thomas McCourt - CEO & Director Michael Shetzline - Chief Medical Officer, SVP and Head, Research & Drug Developme...

The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation

Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q4 Non-GAAP EPS of $0.27 beats by $0.01 . Revenue of $107.2M (-8.5% Y/Y) misses by $1.02M . For FY23, expected revenue is $420 to $435 million, vs. consensus of $426.65M. U.S. LINZESS Net Sales Growth of...

– 2022 GAAP and non-GAAP net income of $175 million – – 2022 adjusted EBITDA of $252 million; ended 2022 with $656 million in cash and cash equivalents – – FDA granted priority review to the sNDA for LINZESS® (linaclotide) for the treatm...

The U.S. Food and Drug Administration (FDA) granted priority review to AbbVie ( NYSE: ABBV ) and Ironwood Pharmaceuticals' ( NASDAQ: IRWD ) application seeking expanded approval of Linzess (linaclotide) to treat children and adolescents aged six years to 17 years with functio...

– FDA assigns 2 nd Quarter 2023 target action date – – If approved, LINZESS would be the first and only FDA-approved prescription therapy for functional constipation in this patient population – – Functional constipation affects an estimated ...

In stock investing, it's easy to focus on big names and blue-chip companies since they are frequently reported in financial media. Conversely, smaller companies, but with promising businesses, tend to be ignored. The latter have smaller market capitalizations and usually trade at more affordable ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 16, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (...